Pipeline von Trovagene sollte man beobachten!
Zahlen für Q3/22
- keine Umsätze
- Verlust 9 Mio. $
- Cash 114 Mio. $
- MK 58 Mio. $
-projected runway into 2025
https://cardiffoncology.investorroom.com/...Provides-Business-Updates
Optionen
| Boardmail an "Vassago" |
Wertpapier: Cardiff Oncology |
Zahlen für Q2/23
- kein Umsatz
- Verlust 11 Mio. $
- Cash 89 Mio. $
- MK 51 Mio. $
- to fund its operations into 2025
https://cardiffoncology.investorroom.com/...-Provides-Business-Update
Optionen
| Boardmail an "Vassago" |
Wertpapier: Cardiff Oncology |
Zahlen für Q3/23
- Umsatz 0,1 Mio. $
- Verlust 9,7 Mio. $
- Cash 81 Mio. $
- MK 43 Mio. $
- to fund its operations into 2025
- Expanded relationship with Pfizer, which will provide clinical execution of new Phase 2 randomized first-line mCRC trial of onvansertib + standard-of-care (SoC) versus SoC, with interim topline data expected in mid-2024
https://cardiffoncology.investorroom.com/...-Provides-Business-Update
Optionen
| Boardmail an "Vassago" |
Wertpapier: Cardiff Oncology |